CVS Health Corp (CVS)

CVS (NYSE:Health Services) EQUITY
$104.14
pos +0.27
+0.26%
Today's Range: 104.01 - 104.84 | CVS Avg Daily Volume: 4,722,200
Last Update: 03/02/15 - 11:54 AM EST
Volume: 973,997
YTD Performance: 7.85%
Open: $104.29
Previous Close: $103.87
52 Week Range: $72.05 - $104.52
Oustanding Shares: 1,125,252,739
Market Cap: 117,217,577,822
6-Month Chart
TheStreet Ratings Grade for CVS
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 14 14 14 13
Moderate Buy 3 3 3 3
Hold 2 2 2 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.34 1.34 1.34 1.45
Latest Dividend: 0.35
Latest Dividend Yield: 1.34%
Dividend Ex-Date: 01/20/15
Price Earnings Ratio: 26.31
Price Earnings Comparisons:
CVS Sector Avg. S&P 500
26.31 26.30 26.52
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
14.28% 43.94% 133.26%
GROWTH 12 Mo 3 Yr CAGR
Revenue 9.90 0.30 0.09
Net Income 1.10 0.33 0.10
EPS 5.90 0.54 0.15
Earnings for CVS:
EBITDA 10.73B
Revenue 139.37B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $1.07 $1.25 $5.15 $5.81
Number of Analysts 11 11 13 14
High Estimate $1.08 $1.30 $5.17 $6.06
Low Estimate $1.06 $1.20 $5.10 $5.43
Prior Year $1.02 $1.13 $4.22 $5.15
Growth Rate (Year over Year) 5.26% 10.86% 21.95% 12.98%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
A lot of stocks are doing incredibly well. 
Cybersecurity, retail among the most fashionable.
The 'dead bodies' are adding up.
Bullish
Jan 21, 2015 | 8:34 AM EST
CVS was upgraded to Buy, Goldman Sachs said. $113 price target. Company can deliver consistent 15% annual earnings growth. 
Two analysts predicted the big rise in Netflix. Well done.
These store-based U.S. retailers are an eclectic mix.

Why I'm Sticking With Biotech Real Money Pro($)

They offer a nice shelter for the headwinds now hitting equities.

Gilead Is a Buying Opportunity Real Money Pro($)

Its hepatitis C drug is better; the stock trades at a discount.
And stop chasing stocks that won't let you in.
Let's look at the other groups that caught fire.

Columnist Conversations

While TWTR remains on my Best Ideas List and has been a gret performer, I have sold calls against the balance ...
HLSS trades above its proposed acquisition price. I dont expect competing bids - after doing some more work on...
"With the NASDAQ finally back to 5000, its noteworthy to look at the market cap of the largest component, Appl...
I have been buying EVERY dip on Citigroup over the last six months. I would no longer chase the shares over $5...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.